Personalized Biologic Therapy for Refractory Bullous Pemphigoid: Sequential Omalizumab, Dupilumab, and Rituximab
Clinical, Cosmetic and Investigational Dermatology · 2026-07 · Volume 19 · 1-5
DOI: 10.2147/ccid.s599596 ↗Kurz gefasst
Fallbericht in der Zeitschrift Clinical, Cosmetic and Investigational Dermatology, 2026-07. Verfasst von Lang Yu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Jianghan University School of Medicine, Wuhan, People's Republic of China. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Jianghan University School of Medicine, Wuhan, People's Republic of China.
- Department of Dermatology, Traditional Chinese and Western Medicine Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
- Department of Dermatology, Wuhan No.1 Hospital, Wuhan, People's Republic of China.
ORCID-Profile: Quanhong Zhang, Yue Zhu, Jinbo Chen
Zitieren
APA
Yu, L., Hu, G., Zhang, Q., Zhu, Y., Chen, L., & Chen, J. (2026). Personalized Biologic Therapy for Refractory Bullous Pemphigoid: Sequential Omalizumab, Dupilumab, and Rituximab. Clinical, Cosmetic and Investigational Dermatology, Volume 19, 1-5. https://doi.org/10.2147/ccid.s599596
Vancouver
Yu L, Hu G, Zhang Q, Zhu Y, Chen L, Chen J. Personalized Biologic Therapy for Refractory Bullous Pemphigoid: Sequential Omalizumab, Dupilumab, and Rituximab. Clinical, Cosmetic and Investigational Dermatology. 2026;Volume 19:1-5. doi:10.2147/ccid.s599596
BibTeX
@article{Yu2026,
author = {Yu, Lang and Hu, Gang and Zhang, Quanhong and Zhu, Yue and Chen, Liuqing and Chen, Jinbo},
title = {Personalized Biologic Therapy for Refractory Bullous Pemphigoid: Sequential Omalizumab, Dupilumab, and Rituximab},
journal = {Clinical, Cosmetic and Investigational Dermatology},
year = {2026},
volume = {Volume 19},
pages = {1--5},
doi = {10.2147/ccid.s599596}
}
EUVIMED